128 related articles for article (PubMed ID: 20626362)
1. Infliximab therapy in children with Crohn's disease: a one-year evaluation of efficacy comparing 'top-down' and 'step-up' strategies.
Kim MJ; Lee JS; Lee JH; Kim JY; Choe YH
Acta Paediatr; 2011 Mar; 100(3):451-5. PubMed ID: 20626362
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of maintenance infliximab therapy for moderate-to-severe Crohn's disease in children: REACH open-label extension.
Hyams J; Walters TD; Crandall W; Kugathasan S; Griffiths A; Blank M; Johanns J; Lang Y; Markowitz J; Cohen S; Winter HS; Veereman-Wauters G; Ferry G; Baldassano R
Curr Med Res Opin; 2011 Mar; 27(3):651-62. PubMed ID: 21241207
[TBL] [Abstract][Full Text] [Related]
3. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.
Borrelli O; Bascietto C; Viola F; Bueno de Mesquita M; Barbato M; Mancini V; Bosco S; Cucchiara S
Dig Liver Dis; 2004 May; 36(5):342-7. PubMed ID: 15191204
[TBL] [Abstract][Full Text] [Related]
4. Infliximab improves inflammation and anthropometric measures in pediatric Crohn's disease.
Sinitsky DM; Lemberg DA; Leach ST; Bohane TD; Jackson R; Day AS
J Gastroenterol Hepatol; 2010 Apr; 25(4):810-6. PubMed ID: 20492339
[TBL] [Abstract][Full Text] [Related]
5. Short-term study of infliximab treatment for Crohn's disease in China.
Zheng JJ; Zhi P; Wang YM; Zhu F; Gu W; Xing YC; Zhou CL; Shen BW
J Dig Dis; 2011 Apr; 12(2):105-9. PubMed ID: 21401895
[TBL] [Abstract][Full Text] [Related]
6. What is the optimal therapy for Crohn's disease: step-up or top-down?
Lin MV; Blonski W; Lichtenstein GR
Expert Rev Gastroenterol Hepatol; 2010 Apr; 4(2):167-80. PubMed ID: 20350264
[TBL] [Abstract][Full Text] [Related]
7. [Top-down versus Step-Up: new strategies in the treatment of Crohn's disease].
Meier J; Sturm A
Z Gastroenterol; 2009 Feb; 47(2):240-2. PubMed ID: 19197829
[No Abstract] [Full Text] [Related]
8. Maintenance of clinical benefit in Crohn's disease patients after discontinuation of infliximab: long-term follow-up of a single centre cohort.
Waugh AW; Garg S; Matic K; Gramlich L; Wong C; Sadowski DC; Millan M; Bailey R; Todoruk D; Cherry R; Teshima CW; Dieleman L; Fedorak RN
Aliment Pharmacol Ther; 2010 Nov; 32(9):1129-34. PubMed ID: 20807218
[TBL] [Abstract][Full Text] [Related]
9. Medical therapy for Crohn's disease: top-down or step-up?
Baert F; Caprilli R; Angelucci E
Dig Dis; 2007; 25(3):260-6. PubMed ID: 17827952
[TBL] [Abstract][Full Text] [Related]
10. The duration of effect of infliximab maintenance treatment in paediatric Crohn's disease is limited.
De Bie CI; Hummel TZ; Kindermann A; Kokke FT; Damen GM; Kneepkens CM; Van Rheenen PF; Schweizer JJ; Hoekstra JH; Norbruis OF; Tjon A Ten WE; Vreugdenhil AC; Deckers-Kocken JM; Gijsbers CF; Escher JC; De Ridder L
Aliment Pharmacol Ther; 2011 Jan; 33(2):243-50. PubMed ID: 21083595
[TBL] [Abstract][Full Text] [Related]
11. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children.
Hyams J; Crandall W; Kugathasan S; Griffiths A; Olson A; Johanns J; Liu G; Travers S; Heuschkel R; Markowitz J; Cohen S; Winter H; Veereman-Wauters G; Ferry G; Baldassano R;
Gastroenterology; 2007 Mar; 132(3):863-73; quiz 1165-6. PubMed ID: 17324398
[TBL] [Abstract][Full Text] [Related]
12. [Treatment of Crohn's disease by infliximab. About 20 cases].
Serghini M; Karoui S; Meknini M; Matri S; Kallel L; Fekih M; Boubaker J; Filali A
Tunis Med; 2009 Sep; 87(9):579-82. PubMed ID: 20180377
[TBL] [Abstract][Full Text] [Related]
13. Biological therapies in inflammatory bowel disease: top-down or bottom-up?
Oldenburg B; Hommes D
Curr Opin Gastroenterol; 2007 Jul; 23(4):395-9. PubMed ID: 17545775
[TBL] [Abstract][Full Text] [Related]
14. [Infliximab therapy in children and adolescents with refractory Crohn's disease in the Netherlands; experience with 23 patients].
de Ridder L; Escher JC; Taminiau JA
Ned Tijdschr Geneeskd; 2002 Oct; 146(40):1879-83. PubMed ID: 12395595
[TBL] [Abstract][Full Text] [Related]
15. [The clinical and endoscopic efficacy of step-up and top-down infliximab therapy in Crohn's disease].
Xiao YL; Chen BL; He Y; Gao X; Huang MJ; Hu PJ; Chen MH
Zhonghua Nei Ke Za Zhi; 2012 Feb; 51(2):100-3. PubMed ID: 22490808
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of infliximab in Brazilian children and adolescents with Crohn disease and ulcerative colitis according to clinical manifestations, activity indices of inflammatory bowel disease, and corticosteroid use.
Tiemi J; Komati S; Sdepanian VL
J Pediatr Gastroenterol Nutr; 2010 Jun; 50(6):628-33. PubMed ID: 20386321
[TBL] [Abstract][Full Text] [Related]
17. 12-month follow-up after successful infliximab therapy in pediatric crohn disease.
Wynands J; Belbouab R; Candon S; Talbotec C; Mougenot JF; Chatenoud L; Schmitz J; Cézard JP; Goulet O; Hugot JP; Ruemmele FM
J Pediatr Gastroenterol Nutr; 2008 Mar; 46(3):293-8. PubMed ID: 18376247
[TBL] [Abstract][Full Text] [Related]
18. A 5-year prospective observational study of the outcomes of international treatment guidelines for Crohn's disease.
Cullen G; Keegan D; Mulcahy HE; O'Donoghue DP
Clin Gastroenterol Hepatol; 2009 Mar; 7(3):323-8; quiz 252. PubMed ID: 19174193
[TBL] [Abstract][Full Text] [Related]
19. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease.
Maser EA; Villela R; Silverberg MS; Greenberg GR
Clin Gastroenterol Hepatol; 2006 Oct; 4(10):1248-54. PubMed ID: 16931170
[TBL] [Abstract][Full Text] [Related]
20. Fistulating anal Crohn's disease: results of combined surgical and infliximab treatment.
Hyder SA; Travis SP; Jewell DP; McC Mortensen NJ; George BD
Dis Colon Rectum; 2006 Dec; 49(12):1837-41. PubMed ID: 17041753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
